Scarica l'app Stockscreener
27.97
1.19%
0.33
Dopo l'orario di chiusura:
28.40
0.43
+1.54%
Rapport Therapeutics Inc Borsa (RAPP) Ultime notizie
Understanding Momentum Shifts in (RAPP) - Stock Traders Daily
RSI Check: What hedge funds are buying Rapport Therapeutics IncM&A Rumor & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn
A Look At Rapport Therapeutics (RAPP) Valuation After Fresh Overweight Rating From Wells Fargo - Sahm
Rapport Therapeutics (NASDAQ:RAPP) Stock Rating Lowered by Wall Street Zen - Defense World
Rapport Therapeutics Completes Key Phase 2a Epilepsy Study for RAP-219: What Investors Should Watch Next - TipRanks
Rapport Therapeutics (NASDAQ:RAPP) Now Covered by Analysts at Wells Fargo & Company - Defense World
Wells Fargo Initiates Coverage of Rapport Therapeutics (RAPP) with Overweight Recommendation - Nasdaq
Rapport Therapeutics (RAPP): Analyst Initiates Coverage with Ove - GuruFocus
Wells Fargo Initiates Coverage on Rapport Therapeutics With Overweight Rating, $43 Price Target - marketscreener.com
Wells Fargo & Company Begins Coverage on Rapport Therapeutics (NASDAQ:RAPP) - MarketBeat
Aug Final Week: What are Rapport Therapeutics Inc.’s technical support levels2025 Market WrapUp & Free Expert Approved Momentum Trade Ideas - baoquankhu1.vn
Whale Trades: What is the dividend yield of PMGC Holdings IncWeekly Trading Summary & Fast Gain Swing Alerts - baoquankhu1.vn
Aug Breakouts: Why is Rapport Therapeutics Inc stock going upStock Surge & Accurate Intraday Trading Signals - baoquankhu1.vn
Activity Recap: What hedge funds are buying Rapport Therapeutics IncJuly 2025 PreEarnings & Free Long-Term Investment Growth Plans - baoquankhu1.vn
Rapport Therapeutics, Inc. (RAPP) Stock Analysis: Promising Biotech with Nearly 95% Upside Potential - DirectorsTalk Interviews
Will Rapport Therapeutics Inc. stock gain from strong economyMarket Trend Review & Verified Stock Trade Ideas - mfd.ru
Should I buy Rapport Therapeutics Inc. stock nowCEO Change & Intraday High Probability Setup Alerts - mfd.ru
Is Rapport Therapeutics Inc. undervalued by DCF analysis2025 Fundamental Recap & Intraday High Probability Setup Alerts - mfd.ru
Layoff Watch: Is Rapport Therapeutics Inc gaining market shareQuarterly Portfolio Summary & Free Community Supported Trade Ideas - baoquankhu1.vn
Avoiding Lag: Real-Time Signals in (RAPP) Movement - Stock Traders Daily
Retail Surge: Is Rapport Therapeutics Inc gaining market shareWeekly Stock Summary & Expert Approved Trade Ideas - baoquankhu1.vn
Rapport Therapeutics (NASDAQ:RAPP) Upgraded to Hold at Wall Street Zen - MarketBeat
JonesTrading Maintains Rapport Therapeutics(RAPP.US) With Buy Rating, Maintains Target Price $50 - 富途牛牛
Rapport Therapeutics, Inc. (RAPP): Investor Outlook With An 87% Potential Upside - DirectorsTalk Interviews
Rapport Therapeutics CEO Ceesay sells $285k in shares By Investing.com - Investing.com Australia
Abraham Ceesay Sells 5,833 Shares of Rapport Therapeutics (NASDAQ:RAPP) Stock - MarketBeat
Rapport Therapeutics CEO Ceesay sells $285k in shares - Investing.com
Short Interest in Rapport Therapeutics, Inc. (NASDAQ:RAPP) Expands By 20.7% - Defense World
Rapport Therapeutics, Inc. (NASDAQ:RAPP) Short Interest Up 20.7% in December - MarketBeat
Rapport Therapeutics, Inc. (NASDAQ:RAPP) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
David Bredt Sells 8,500 Shares of Rapport Therapeutics (NASDAQ:RAPP) Stock - Defense World
Rapport Therapeutics (RAPP) Is Down 7.4% After Advancing RAP-219 Toward Phase 3 In Epilepsy - Sahm
Rapport Therapeutics (NASDAQ:RAPP) Downgraded by Wall Street Zen to "Sell" - MarketBeat
Discipline and Rules-Based Execution in RAPP Response - Stock Traders Daily
Insider Sell: David Bredt Sells 8,500 Shares of Rapport Therapeu - GuruFocus
Rapport Therapeutics (NASDAQ:RAPP) Insider David Bredt Sells 8,500 Shares - MarketBeat
Rapport Therapeutics, Inc. (RAPP) Stock Analysis: A Biotech With 94.53% Potential Upside - DirectorsTalk Interviews
Rapport Reveals Pricing for Public Common Stock Offering - Intellectia AI
A Look At Rapport Therapeutics (RAPP) Valuation After FDA Clears Phase 3 Trial For RAP-219 - Sahm
Rapport Therapeutics (NASDAQ:RAPP) Trading Down 6.9%Time to Sell? - MarketBeat
Rapport Therapeutics: Diversified Neurology Pipeline and Accelerated RAP-219 Development Underpin Buy Rating - TipRanks
FDA Phase 3 Green Light for RAP-219 Might Change The Case For Investing In Rapport Therapeutics (RAPP) - Sahm
Will Rapport Therapeutics Inc. stock outperform growth indexesJuly 2025 Sector Moves & Safe Capital Growth Tips - Улправда
Rapport Therapeutics, Inc. (RAPP): Investor Outlook with a Promising 84.56% Potential Upside - DirectorsTalk Interviews
Is Rapport Therapeutics Inc. stock a smart buy before Fed meeting2025 Sector Review & Free Expert Approved Momentum Trade Ideas - ulpravda.ru
Can Rapport Therapeutics Inc. stock resist market sell offsQuarterly Portfolio Review & Risk Managed Investment Entry Signals - ulpravda.ru
Form 8-KCurrent report - ADVFN
Rapport Therapeutics (RAPP) Refocuses Neurology Pipeline After RAP-219 Phase 3 Greenlight – What’s the R&D Tradeoff? - Yahoo Finance
A Quick Look at Today's Ratings for Rapport Therapeutics(RAPP.US), With a Forecast Between $40 to $56 - 富途牛牛
Rapport Therapeutics: Accelerated RAP-219 Epilepsy Path to Phase 3 and Strategic Pipeline Refocus Support Buy Rating - TipRanks
Citizens reiterates Market Outperform rating on Rapport Therapeutics stock By Investing.com - Investing.com Canada
Rapport Therapeutics (RAPP) Receives FDA Clearance to Advance RAP-219 into Phase 3 Trials - Intellectia AI
Rapport To Advance Phase 3 Program Of RAP-219 In Focal Onset Seizures In Q2 - Nasdaq
Los Angeles Daily NewsRapport Therapeutics, Inc.Common Stock (Nasdaq:RAPP) Stock Quote - FinancialContent
Assessing Rapport Therapeutics (RAPP) Valuation After Recent Share Price Strength - Yahoo Finance
1.24%
0.19%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):